The presence of thyroid peroxidase antibodies (TPO-Ab) before treatment was identified as a risk factor for the incidence of thyroid disease in 60% of HCV patients receiving IFN α [28]. This evidence concerns the gene IFNA1 and thyroid gland disorder.